- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01974336
The Preventative and Therapeutical Effect of Ursodeoxycholic Acid(UDCA) to Short Bowel Syndrome Patients
February 23, 2017 updated by: Kong Wencheng, Jinling Hospital, China
The Preventative and Therapeutical Effect of Ursodeoxycholic Acid(UDCA) to Parenteral Nutrition-associated Cholestasis in Short Bowel Syndrome
The efficacy of UDCA in treating the parenteral nutrition-associated cholestasis(PNAC) has been identified by some studies in children without short bowel syndrome(SBS).Most of the adults who suffering PNAC have SBS. it limits the potential function of UDCA because of the lack of SBS patients and malabsorption of UDCA.Therefore, we design this clinical trial in our center of SBS to approach the preventative and therapeutical effect of UDCA to PNAC in adults with short bowel syndrome.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
30
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Jiangsu
-
Nanjing, Jiangsu, China, 200002
- Jinling Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years to 68 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patients with short bowel syndrome supported by total parenteral nutrition.
- Patients have intestine more than 50cm.
- Requirements of informed consent and assent of participant, parent or legal guardian as applicable
- Consciousness and ability to cooperate.
Exclusion Criteria:
- Patients have obstruction of biliary tract, infection, autoimmune disease, cancer
- Patients have intestine less than 50cm
- A clinically significant laboratory abnormality or a history of significant cardiac, pulmonary, hepatic, or renal disease
- Female with positive pregnancy
- Allergy to ursodeoxycholic acid
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: UDCA+placebo group
15-30mg/kg/d UDCA for 2 months + placebo for 2 months
|
|
Experimental: placebo+UDCA
placebo for 2 months+15-30mg/kg/d UDCA for 2 months
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The biochemical indicator of patients' liver function during oral UDCA or placebo
Time Frame: 2 months
|
detect the biochemical indicator of patients' liver function(Serum bilirubin, GGT Valley, lactate dehydrogenase, alanine aminotransferase, aspartate aminotransferase) during oral UDCA or placebo
|
2 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
the changs of composition of serum bile acid after oral UDCA or placebo
Time Frame: 2 months
|
we test the composition of serum bile acid at the beginning,2 months,4 months(the end) of the trial
|
2 months
|
The changs of the level of fibroblast growth factor 19(FGF19) in the serum
Time Frame: 4 months
|
we test the level of FGF19 in the serum at the beginning,2 months,4months(the end) of the trail.
|
4 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Wencheng Kong, MD, Nanjing University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 1, 2013
Primary Completion (Actual)
April 1, 2016
Study Completion (Actual)
September 1, 2016
Study Registration Dates
First Submitted
October 20, 2013
First Submitted That Met QC Criteria
October 26, 2013
First Posted (Estimate)
November 1, 2013
Study Record Updates
Last Update Posted (Actual)
February 24, 2017
Last Update Submitted That Met QC Criteria
February 23, 2017
Last Verified
February 1, 2017
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- UDCA-PNAC-SBS
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Short Bowel Syndrome
-
Marathon Pharmaceuticals, LLCWithdrawnShort Bowel Syndrome | Short Gut Syndrome | SBS | Short Gut | Short BowelUnited States
-
Central Hospital, Nancy, FranceBeaujon Hospital; Société Francophone Nutrition Clinique et MétabolismeUnknownSBS - Short Bowel SyndromeFrance
-
TakedaRecruitingShort Bowel Syndrome (SBS)Canada
-
GlyPharma TherapeuticsVectivBio AGCompletedSBS - Short Bowel SyndromeDenmark
-
TakedaCompletedShort Bowel Syndrome (SBS)Brazil
-
ShireRecruitingShort Bowel Syndrome (SBS)United States
-
Marathon Pharmaceuticals, LLCWithdrawnShort Bowel Syndrome | Short Gut Syndrome | SBS | Short GutUnited States
-
University of Texas Southwestern Medical CenterChildren's Hospital of PhiladelphiaEnrolling by invitationShort Gut SyndromeUnited States
-
Children's Hospital of PhiladelphiaUniversity of PennsylvaniaRecruiting
-
University of MiamiQOL Medical, LLCRecruitingShort Gut SyndromeUnited States
Clinical Trials on ursodeoxycholic acid
-
Mitsubishi Tanabe Pharma CorporationCompletedChronic Hepatitis CJapan
-
University of Sao Paulo General HospitalCompletedPrimary Biliary Cirrhosis | Ursodeoxycholic AcidBrazil
-
University of TennesseeUniversity of Colorado, Denver; Baylor College of Medicine; Children's Hospital... and other collaboratorsCompletedPrimary Sclerosing CholangitisUnited States
-
West China HospitalUnknownHepatitis | Autoimmune | Primary Biliary CholangitisChina
-
Daewoong Pharmaceutical Co. LTD.CompletedHealthy SubjectKorea, Democratic People's Republic of
-
Institute of Hematology & Blood Diseases HospitalCompleted
-
Turku University HospitalCompletedPregnancy | Intrahepatic CholestasisFinland
-
HaEmek Medical Center, IsraelUnknown
-
Nottingham University Hospitals NHS TrustTerminated
-
Tanta UniversityMenoufia UniversityRecruiting